Journal of Ophthalmology / 2016 / Article / Tab 2

Research Article

Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma

Table 2

NVG patient backgrounds according to treatment received. The majority of patients in the LEC group had stage 3 NVG and had previously received other treatments, such as adequate PRP, stand-alone anti-VEGF therapy, and PPV. Approximately half (41.2%) of patients that received frequent stand-alone anti-VEGF treatment had previously received repeated anti-VEGF injections.

TreatmentsAnti-VEGF stand-alone therapyAdditional PRPPPVLEC

Number of treatments17892832

Anti-VEGF combination therapy ()49153

Pre-treatment IOP (mmHg)36.1 ± 12.536.1 ± 13.533.7 ± 13.935.0 ± 8.1

Criteria
 Rubeosis group1 (5.9%)9 (10.1%)4 (14.3%)1 (3.1%)
 Open-angle NVG group 10 (58.8%)51 (57.3%)12 (42.9%)8 (25.0%)
 Angle-closure NVG group 6 (35.3%)12 (32.6%)12 (42.9%)23 (71.9%)

Previous treatment
 Anti-VEGF stand-alone therapy7 (41.2%)1 (1.1%)3 (10.7%)23 (71.9%)
 PRP17 (100.0%)(44.9%)(85.7%)32 (100.0%)
 PPV4 (23.5%)0 (0%)0 (0%)7 (21.9%)
 LEC1 (5.9%)0 (0%)0 (0%)1 (3.1%)

Follow-up  
(pre-treatment, months)
2.5 ± 2.8
0.0 to 8.3
0.8 ± 3.0 
0.0 to 22.3
3.2 ± 7.9
1.0 to 33.3
7.2 ± 11.5
0.0 to 48.8

Follow-up  
(post-treatment, months)
21.0 ± 19.7 
4.1–53.2
25.4 ± 21.6 
4.0–81.8
25.0 ± 14.3 
5.1–56.0
24.5 ± 22.6 
4.3–60.7

PRP, panretinal laser photocoagulation; PPV, pars plana vitrectomy, LEC, trabeculectomy with mitomycin C.
Mean ± SD, Steel-Dwass test for PDR, for OIS.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.